LUNG CANCER

Targeting multiple immune cell pathways may elicit better major pathologic and pathologic complete responses in patient with resectable, early-stage non–small cell lung cancer versus immune checkpoint inhibition alone.

During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.

Solange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.

Four-year follow-up data from the KEYNOTE-042 show promising survival and durable response in patients with non–small cell lung cancer.

The PROPHETIC trial of a predictive diagnostic analysis platform expanded to a new site at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

Acclaim-2 has opened enrollment for patients with late-stage non-small cell lung cancer and will begin screening patients for their eligibility to participate in the trial.

The combination of RBN-2397 and pembrolizumab has been dosed in the first patient with squamous cell carcinoma of the lung who is enrolled in a new phase 1b/2 clinical trial.

Use of trilaciclib prior to chemotherapy demonstrated a substantial burden of myelosuppressive hematologic adverse events within the patients with extensive-stage small-cell lung cancer.

A significant proportion of patients who complete 2 years of immune checkpoint inhibitor treatment experience long-term progression-free survival.

The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.

With larotrectinib treatment, patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Findings show adjuvant pembrolizumab to significantly improve disease-free survival in patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

The FDA has approved the FoundationOne CDx as a companion diagnostic to identify patients with non–small cell lung cancer with tumors that harbor EGFR exon 19 deletions or exon 21 substitutions.

During a Targeted Oncology case-based roundtable event, David P. Carbone, MD, PhD, discussed molecular testing and treatment for a patient with late-stage non–small cell lung cancer.

Adding toripalimab to chemotherapy as frontline treatment for advanced non–small cell lung cancer crossed the boundary for statistical significance in CHOICE-01, meeting 2 study end points.

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

Dosing has begun in patients with advanced non–small cell lung cancer in the phase 1/2 Acclaim-1 clinical trial of quaratusugene ozeplasmid in combination with osimertinib after disease progression on osimertinib alone.

Nivolumab in combination with platinum-doublet chemotherapy has been granted FDA approval as neoadjuvant treatment for adult patients with resectable non-small cell lung cancer.

Solange Peters, MD, PhD, discusses the design of the CheckMate743 study of doublet immunotherapy for patients with malignant pleural mesothelioma.

According to retrospective data, racial disparities among patients being screened for lung cancer have decreased.

Jorge Nieva, MD, explains how international drug developers should approach the approval application process after a biologics license application for sintilimab plus chemotherapy for the treatment of nonsquamous non–small cell lung cancer was not successful.

The FDA will conduct a speedy review of the supplemental biologics license application filed for nivolumab in combination with chemotherapy and granted it priority review for the neoadjuvant treatment of patients with resectable non–small cell lung cancer.

Jorge Nieva, MD, discusses how a future clinical trial of sintilimab injection plus chemotherapy should look in order to achieve FDA approval for the treatment of patients with nonsquamous non–small cell lung cancer.